American Century ETF Trust Avantis U.S. Large Cap Equity ETF (ARCA: AVLC)

Latest news for American Century ETF Trust Avantis U.S. Large Cap Equity ETF (ARCA:AVLC)

Technology

Financial Services

Consumer Cyclical

Industrials

Healthcare

Energy

Consumer Defensive

Communication Services

Basic Materials

Utilities

Other

Real Estate

The fund invests primarily in a diverse group of U.S. companies across market sectors and industry groups. The fund seeks securities of companies that it expects to have higher returns by placing an enhanced emphasis on securities of companies with higher profitability and value characteristics. Conversely, the fund seeks to underweight or exclude securities it expects to have lower returns, such as securities of companies with lower levels of profitability and less attractive value characteristics.

Apple, Inc

Microsoft Corp

Nvidia Corp.

Amazon.Com Inc

Meta Platforms, Inc.

Alphabet Inc,class A

Alphabet Inc.

Exxon Mobil Corp - Common

Jpmorgan Chase & Co (jpm)

Broadcom Inc

Avantis US Large Cap Equity ETF

American Century ETF Trust Avantis U.S. Large Cap Equity ETF

Porch Group, Inc. ("Porch" or "the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>), a homeowners insurance and vertical software platform, today announced Porch Group Media ("PGM"), the data and marketing subsidiary of Porch, has signed an agreement to license non-exclusively its unique Home Factors insights to California-based insurance MGA, Bamboo Ide8 Insurance Services, LLC. ("Bamboo").
This agreement follows the recent announcement of Home Factors' official third-party launch in the market. Porch Group Media has Home Factors for approximately 90% of US homes, providing unique and valuable insights not previously available. For example, identifying that an electric panel needs repair indicates 41% higher claims frequency. These insights have already demonstrated strong performance with Porch's own insurance carrier, Homeowners of America Insurance Company ("HOA"), where it has contributed to its improvement in loss ratio performance.
Home Factors provides value for consumers and carriers. Consumers can get fairer prices based on the actual risk of their property and insurance carriers are expected to achieve more accurate pricing and lower underwriting costs. Tests with HOA and other third-party partners such as Bamboo continue to validate Home Factors' value in underwriting, rate, claims, marketing and overall risk management. Bamboo is among the first to leverage Home Factors insights for a tech-forward and data-driven approach to underwriting, and reduce the cost of manual underwriting.

News

PRCH

Porch Group Has Signed An Agreement To License Non-Exclusively Its Unique Home Factors Insights To California-based Insurance MGA, Bamboo Ide8 Insurance Services

WIIM

NXTC

NextCure shares are trading higher after the company highlighted data demonstrating that NC605 resulted in enhanced generation of quality bone and better mechanical properties.

Dear Fellow Stockholder,
Given my recent transition to the role of CEO, I wanted to share my thoughts on Coya and our future and to express my gratitude to our founder and Executive Chair, Dr. Howard Berman, whose bold vision has instilled the "innovation and get-it-done" culture in Coya's DNA. We have made tremendous strides in 2024, repeatedly executing on our promises. As I look to 2025, I am confident that our nimble and highly experienced team will continue to exceed expectations.
I have spent my entire 25-year career in the biotech space, and I believe that Coya has the most promise of any company that I have represented. I truly believe our novel science, strong clinical proof of concept data, pharmaceutical partnership validation, cash runway, and clear path to a commercial drug differentiates us. Prior to serving at Coya, I helped spearhead and lead pharmaceutical transactions worth billions of dollars that led to significant value creation. I believe the opportunities ahead of us in 2025 and beyond are what investors, stockholders, and patients should be most excited about. Our science and approach of regulating Tregs is now validated in multiple trials across multiple neurodegenerative diseases, we have a track record of executing value-creating non-dilutive deals, and our strong cash position allows us to be prudent in our decisions.
Year Ahead
We expect our activities in 2025 to be focused on the following indications:
ALS (Amyotrophic Lateral Sclerosis) Program: We have alignment with the FDA on the data required to initiate our potentially pivotal COYA 302 Phase 2 double-blind randomized study in patients with ALS. We are targeting the submission of the requested data package by 2Q 2025 and initiation of the clinical trial upon FDA clearance. The roadmap to topline results is now clear with reduced uncertainty. In late 2023, we partnered with Dr. Reddy's Laboratories, a multi-billion-dollar drug developer, to license COYA 302 in ALS in a deal that is worth up to $700 million. We still retain the rights to COYA 302 in ALS in Japan and South/Central America and Mexico, thus providing us direct upside and optionality in this indication alone.
FTD (Frontotemporal Dementia) Program: We expect to see topline results in 2H 2025 from the investigator-initiated, open-label study of Low Dose IL-2 (LD IL-2) + CTLA4-Ig in FTD. Study endpoints will measure safety, peripheral and central inflammation, FTD progression, and pharmacodynamic effects on Treg cell populations. The data are expected to guide our planned COYA 302 Phase 2 double-blind randomized study (which will be funded by the Alzheimer's Drug Discovery Foundation) and further optimize the design for success. The guidance from the FDA on the ALS IND reduces uncertainty on the planned IND filing for FTD in 2H of 2025. We have retained full commercial rights on this program thus far, providing us optionality to develop the program to BLA approval ourselves and capture the full potential upside or partner at a later stage once we obtain additional clinical data.
AD (Alzheimer's disease) Program: Complementing the promising data that was presented at CTAD in Madrid for LD IL-2 in mild to moderate AD, the investigators will disclose additional data in 1H 2025 that summarizes the changes in inflammation in the peripheral system (blood) and central nervous system (CSF and brain) and other molecular measurements for the two IL-2 dosing arms vs. placebo. These important data will help to further address the basic science associated with the promising clinical response observed in the lower dose IL-2 arm and its association with better Treg enhancement. We retain full rights to the AD indication for COYA 302 and are already in the process of exploring non-dilutive and strategic partnering opportunities. While the CTAD data was based on LD IL-2 alone and proved highly promising in and of itself, COYA 302, which is a proprietary combination of LD IL-2 and CTLA4-Ig, targets multiple pathways and is developed to more significantly and durably enhance Treg function, which we believe will be highly attractive to potential partners.
Strategic Partnerships
Dr. Reddy's Partnership: Our partnership with Dr. Reddy's Laboratories is approaching its one-year anniversary, and our collaboration could not be stronger. We have a reliable partner for ALS, and leveraging its resources and expertise has created value beyond the milestone payments. In 2025, we anticipate receiving $8.4 million upon initiation of the Phase 2 ALS clinical trial and will continue to evaluate opportunities to further deepen the relationship.
Other Strategic Possibilities: As I have described, my background is one of deal-making, and I intend to leverage my network and capabilities to maximize opportunities for Coya in 2025. We have only partnered COYA 302 in ALS, and the optionality to partner, co-develop, or license the asset in other indications exists. Any potential transaction will be evaluated based on maximizing stockholder value. The positive data from the investigator-initiated trial of LD IL-2 in patients with Alzheimer's disease increases our confidence in obtaining value-creating pharma partnerships that combine our proprietary LD IL-2, COYA 301, with other modalities. I can envision multiple opportunities with LD IL-2 serving as a backbone adjuvant with standard of care agents and other novel pathways.
Moreover, the opportunity for grant funding and financial support from foundations exists and will be vigorously pursued. We believe the data emerging on Tregs in autoimmune disease (such as lupus, rheumatoid arthritis, and scleroderma) and, in particular, treatment with LD IL-2 is compelling and may strengthen the role of COYA 302 and LD IL-2 combinations in this space. I intend to actively pursue partnerships in this arena that would further place us in a strong position to pursue value-creating deals.
Value-Creating Pipeline
Like many experts in the scientific community, we believe combination strategies are the future to address devastating neurodegenerative diseases. We believe targeting one mechanism or pathway is likely insufficient to achieve maximal effect - hence our approach with COYA 302. COYA 302 is a "Pipeline within a Product" and has strong potential in ALS, FTD, AD, Parkinson's disease, and other indications.
We are continuously building our intellectual property to further enhance the value of Coya. One recent development is the combination of COYA 301 and GLP-1 agonists. Data suggests that the mechanism of action appears additive and/or synergistic in ameliorating inflammation. This is yet another opportunity for value-creating strategic partnerships. We intend to publish more detailed data in 1Q 2025.
Conclusion
As you can see from our past performance, our entire management team is committed to the success of Coya. We expect to recognize a number of clinical, regulatory, and/or commercial milestones in 2025 that will help us advance the treatment of neurodegenerative diseases.
On behalf of the entire Coya team, please accept our sincere gratitude for both your support and belief in our science, our story, and our team. We look forward to presenting additional clinical data and updating you on our additional corporate developments as they unfold. Onwards and upwards!

COYA

Coya Therapeutics Highlights Strategic Vision Under New CEO, With Key 2025 Milestones Including ALS Trial With Dr. Reddy's Partnership Worth Up To $700M, Emerging Opportunities In Parkinson's And Autoimmune Conditions, And Focus On Non-Dilutive Funding To Advance Treg-Enhancing Biologics For Neurodegenerative And Autoimmune Diseases

Despite ongoing market fluctuations, Rick Rieder, the global CIO of fixed income at BlackRock, has expressed confidence in the continued rise of stock markets, even in the face of high valuations. His insights were shared during a Yahoo Finance conference, where he highlighted the absence of sellers as a crucial factor supporting this trend.
What Happened: Rieder emphasized that despite the allure of money-market funds due to high interest rates, the momentum in stock buying remains robust. He noted that consistent inflows into equities from 401(k)s and other sources continue without significant selling pressure, Business Insider <a href="https://markets.businessinsider.com/news/stocks/rick-rieder-blackrock-stock-market-outlook-commentary-valuations-no-sellers-2024-11">reported</a> on Tuesday.
Corporate buybacks are also playing a pivotal role. Rieder pointed out that major companies have repurchased a trillion dollars worth of their own shares, reducing the equity supply and boosting per-share values. This activity, he argued, more than compensates for any valuation concerns.
See Also: <a href="https://www.benzinga.com/24/11/42022100/trump-media-faces-investor-exodus-as-arc-global-slashes-stake-to-nearly-zero-after-court-ruling?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Major Investor In Trump Media Offloads Most Of Its Stake In DJT Stock</a>
While acknowledging stretched valuations, Rieder suggested that market multiples could normalize if earnings rise significantly. 
&#8220;I think markets tend to react to the shark closest to the boat,&#8221; Rieder said, adding that these are not immediate threats. 
&#8220;I don&#8217;t know if it&#8217;s the latter part of 2025 or the beginning of 2026 unless they address the size of the spending dynamics, the amount of debt we&#8217;re issuing, and, then obviously, inflation relative to that.&#8221;
Why It Matters: The stock market has experienced a series of ups and downs recently. On Monday, U.S. stocks rebounded <a href="https://www.benzinga.com/government/regulations/24/11/42045345/us-stocks-rebound-tesla-rallies-bitcoin-soars-above-92000-whats-driving-markets-monday">after a challenging week,</a> with all 11 sectors of the S&amp;P 500 trading positively. This recovery was driven by a decrease in pressures from the dollar and Treasury yields. Notably, consumer discretionary stocks outperformed, with Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) surging by 7% due to reports of the incoming Donald Trump administration prioritizing a federal framework for autonomous vehicles.
However, geopolitical tensions have recently <a href="https://www.benzinga.com/24/11/42058223/us-stocks-likely-to-open-in-red-as-geopolitical-tension-weigh-on-investor-sentiment-wharton-economist-says-market-trajectory-will-heavily-depend-on-trumps-tariff-plans">weighed on investor sentiment</a>. Today, before the bell, futures of major indices pointed to a cautious stance on Wall Street, influenced by economic data and comments from Federal Reserve Chair Jerome Powell about the future of rate cuts, as well as geopolitical developments, including Russian President Vladimir Putin&#8216;s expanded nuclear doctrine.
Price Action: In premarket trading on Tuesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500 Index, fell 0.35% to $586.11 and the Invesco QQQ ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the Nasdaq 100 Index, declined 0.29% to $498.58, according to <a href="https://benzinga.grsm.io/lxquj26b2sag" target="_blank" rel="noreferrer noopener">Benzinga Pro data</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/42028954/peter-thiel-says-trumps-60-china-tariff-would-be-very-very-bad-for-beijing-heres-whats-at-stake?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Peter Thiel Says Trump&#8217;s 60% China Tariff Would Be &#8216;Very, Very Bad&#8217; For Beijing, Here&#8217;s What&#8217;s At Stake</a></li>
</ul>
Image via Unsplash
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Analyst Color

Markets

General

TSLA

Why BlackRock's Rick Rieder Believes Markets Will Rise Despite Valuation Worries

Management

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Comments On Transaction Rumors; Says 'It Is Aware Of The Rumors That Appeared In The Financial Press Regarding A Potential Transaction Involving The Company. It Is The Company's Policy Not To Comment On Market Rumors Or Speculation'

JP Morgan analyst Al Harvey upgrades Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>) from Neutral to Overweight.

Upgrades

Analyst Ratings

JP Morgan Upgrades Newmont to Overweight

CTVA

Corteva Agriscience shares are trading higher after the company announced a $3 billion share repurchase program.

Earnings

CPOP

Pop Culture Gr FY Sales $47.38M

Oppenheimer analyst Owen Lau maintains Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Outperform and lowers the price target from $315 to $286.

Price Target

Oppenheimer Maintains Outperform on Equifax, Lowers Price Target to $286

Dragonfly Energy Holdings Corp. ("Dragonfly Energy" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>), maker of Battle Born Batteries&#xAE; and an industry leader in energy storage, today, announced today that it will effect a 1-for-9 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on Friday, November 22, 2024. Dragonfly Energy's common stock will continue to trade on The Nasdaq Capital Market under the symbol "DFLI" and under a new CUSIP number, 26145B 304.
As a result of the reverse stock split, every nine pre-split shares of common stock outstanding will become one share of common stock. The par value of Dragonfly Energy's common stock will remain unchanged at $0.0001 per share after the reverse stock split. The reverse stock split will not change the authorized number of shares of Dragonfly Energy's common stock. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder's percentage interest in Dragonfly Energy's equity, except to the extent that the reverse stock split results in some stockholders owning a fractional share. No fractional shares will be issued in connection with the reverse stock split. Instead, in lieu of any fractional shares to which a stockholder of record would otherwise be entitled as a result of the reverse stock split, the Company will issue to such stockholder such additional fraction of a share as is necessary to increase such resulting fractional share to a full share of common stock. The reverse stock split will also apply to common stock issuable upon the exercise of the Company's outstanding warrants and stock options, with a proportionate adjustment to the exercise prices thereof, and under Dragonfly Energy's equity incentive plans.
The reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 63.2 million to approximately 7.0 million.

Stock Split

DFLI

Dragonfly Energy Announces 1-For-9 Reverse Stock Split; Effective For Trading Purposes As Of The Commencement Of Trading On Friday, November 22, 2024

Contracts

SVRE

SaverOne Signs Commercial Agreement With The Spanish Subsidiary Of A Construction Company, Under Which Co. Will Install 200 SaverOne Systems

Lotus Technology Inc. ("Lotus" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>), a leading global intelligent luxury mobility provider, announced that Lotus Robotics, a subsidiary of the Company, has to date achieved a total contract value1 of approximately US$130 million for its intelligent driving solutions, symbolizing a significant driver for the long-term and sustainable growth of the Company.
Lotus Robotics has secured agreements with leading global auto conglomerates across Europe, Japan and other key markets with over 40% of total contract value from Europe and Rest of the World, demonstrating the global market recognition of its self-owned technologies. Close to 10 different models to be delivered to global car owners are expected to be equipped with Lotus Robotics' driving solutions in the next 2-3 years.

Lotus Technology's Lotus Robotics Has To Date Achieved A Total Contract Value Of ~$130M For Its Intelligent Driving Solutions, Symbolizing A Significant Driver For The Long-Term And Sustainable Growth Of The Company

Walmart CEO Says East Coast Port Strikes And Storms Impacted Operating Income Growth Negatively In Q3; CFO Says US Consumers Remain Resilient And Are Largely Consistent In Behaviour Over The Past Four Or Six Quarters; CFO Says In Q3 Company Rolled Back Prices On 6,000 Items

Oppenheimer analyst Jeff Jones maintains Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) with a Outperform and lowers the price target from $14 to $12.

CLRB

Oppenheimer Maintains Outperform on Cellectar Biosciences, Lowers Price Target to $12

JP Morgan analyst Eric Joseph initiates coverage on Septerna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) with a Overweight rating and announces Price Target of $38.

Initiation

SEPN

JP Morgan Initiates Coverage On Septerna with Overweight Rating, Announces Price Target of $38

Benchmark analyst Mark Zgutowicz reiterates Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) with a Buy and maintains $51 price target.

Reiteration

CRTO

Benchmark Reiterates Buy on Criteo, Maintains $51 Price Target

Oppenheimer analyst Noah Kaye maintains Vertiv Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) with a Outperform and raises the price target from $121 to $131.

Oppenheimer Maintains Outperform on Vertiv Hldgs, Raises Price Target to $131

Spectral AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the successful completion of an approximate $5.0 million equity financing in an at-the-market transaction. The closing is to be completed in two tranches. Part of the proceeds will be used for the retirement of its outstanding obligations with Yorkville Advisors. This transaction supports Spectral AI's growth trajectory and progress toward a submission to the U.S. Food and Drug Administration ("FDA") for approval of its DeepView AI&#xAE;-Burn system, a crucial milestone targeted for the first half of 2025.
The equity financing was made possible through a strategic financing arrangement with institutional investors, a testament to Spectral AI's ability to attract significant financial support. This arrangement, which included an at-the-market offering of equity and pre-funded warrants, strengthens Spectral AI's balance sheet and enhances its operational flexibility as it pursues FDA approval.

Offerings

MDAI

Spectral AI Announces The Successful Completion Of An ~$5M Equity Financing In An At-The-Market Transaction, Strengthening Financial Position For FDA Pathway

Health Care

IRIX

Iridex Confirms That Local Coverage Determination L37531, Relating To Micro-Invasive Glaucoma Surgery Was Adopted As Scheduled And wll Be Effective For Services Performed After Nov. 17

Jefferies analyst Michael Prew initiates coverage on InvenTrust Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVT#NYSE">IVT</a>) with a Hold rating and announces Price Target of $33.

Jefferies Initiates Coverage On InvenTrust Properties with Hold Rating, Announces Price Target of $33

Comments

American Century ETF Trust Avantis U.S. Large Cap Equity ETF

News

Latest news for American Century ETF Trust Avantis U.S. Large Cap Equity ETF (ARCA:AVLC)

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga